Debate and Discussion: In the Treatment of Depression, Does Selectivity of Action Matter?

View This PDF

NB: This article is only available as a PDF.

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Dr. Schatzberg: There are 2 overriding issues to be addressed. First is the question of whether there is evidence of differential efficacy for major depression between single-action drugs and drugs that inhibit reuptake of both serotonin and norepinephrine. Second is the question of how to design a trial to evaluate whether one drug has enhanced or superior efficacy over another based on mechanism of action.​​

J Clin Psychiatry 2004;65(suppl 4):60-62